spacer
home > pmps > winter 2018 > open, inhale, close
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Open, Inhale, Close

Open, inhale, close has become the Holy Grail of inhaler designers – anything more demanding being considered likely to negatively influence a patient’s desire or ability to correctly use an inhaler device. Therefore, these three steps set in motion the processes needed to defeat the anatomical and physiological barriers in the lungs and nose for delivery of a drug to a local receptor or one in a remote organ. In short, the job of a pharmaceutical aerosol researcher is to overcome the complex chemical, physical, and biological barriers to drug efficacy using a device patients can and will use. The barriers go beyond science; regulations, cost, human nature, and personal experience all play a role in determining if a patient will indeed open, inhale, close. Not even 30-year veterans of Respiratory Drug Delivery (RDD®) meetings can single-handedly accumulate the vast range of knowledge, skills, and experience needed to develop an inhaled product. Pulmonary and nasal product development demands interdisciplinary collaboration and the active involvement of the patient.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Richard Dalby and Joanne Peart
Co-organisers of RDD 2018
spacer
Richard Dalby
spacer
spacer
spacer
Joanne Peart
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PHARM Connect 2019

Life science and business are going to meet at PHARM Connect on the 12-13 of March 2019 in Budapest, Hungary to continue the tradition of providing high calibre, customised professional partnering opportunities for pharma and biotech professionals from Central & Eastern European and beyond and deliver the crucial information they need to excel in their work. The influential annual gathering brings together over 400 global and regional decision-makers, top scientists, industry executives and business development leaders for the ninth time to identify new business opportunities, technologies, state-of-the-art formulation development strategies and to foster exchange of ideas on the role of the sector.
More info >>

White Papers

Choosing the Right CMO for HPAPI Manufacturing

AMRI

Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem — which CMO should you pick when each is touting similar technical capabilities?
More info >>

 
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: it’s where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today’s hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement